Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
Qian Shi(Mayo Clinic), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Ioannis Boukovinas, Lindsay A. Renfro(Mayo Clinic in Arizona), Daniel J. Sargent(National Institute of Agricultural Botany), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jeffrey A. Meyerhardt(CancerCare), James Paul(Cancer Research UK), Axel Grothey(Mayo Clinic), Takayuki Yoshino(University of Tsukuba), Franck Bonnetain(Azienda Ospedaliera Universitaria Pisana), Ioannis Sougklakos(University Hospital of Heraklion), Anthony F. Shields(Wayne State University), Donna Niedzwiecki(Duke University), Thierry André(Inserm), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino), Rachel Kerr(Cancer Research UK Clinical Trials Unit), Toshiaki Watanabe(National Center For Child Health and Development), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 60
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k